Univest
Univest
  • Markets

Medicamen Biotech Ltd. Hits Lower Circuit on BSE, 24 September 2026

  • September 24, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Medicamen Biotech Ltd. Hits Lower Circuit on BSE, 24 September 2026

On 24 September 2026, Medicamen Biotech Ltd. hit the lower circuit on BSE at Rs 307.75, a 4.99% negative move from the previous close of Rs 323.9. The company’s market cap stood at Rs 439.3 crore. The lower circuit price for the session was Rs 307.75.

The move was driven by selling pressure against the exchange-defined price band. At the time of writing the stock was locked at its lower circuit level, which makes the session worth noting for short-term market participants.

Table of Contents

Toggle
  • Key Takeaways
  • Key Market Data
  • Price Action and Trading Activity
  • Why Medicamen Biotech Ltd. Hit Lower Circuit
  • What the Lower Circuit Means
  • Medicamen Biotech Ltd. Fundamentals and Valuation
  • Peer and Sector Context
  • Technical and Ownership Snapshot
  • What Readers Should Know
  • Frequently Asked Questions
    • Why did Medicamen Biotech Ltd. hit lower circuit on 24 September 2026?
    • What was Medicamen Biotech Ltd. share price on 24 September 2026?
    • What was the lower circuit price for Medicamen Biotech Ltd.?
    • What is Medicamen Biotech Ltd.’s market cap and PE ratio?
    • Which exchange and data source were used?
    • Does hitting a lower circuit mean Medicamen Biotech Ltd. is a buy or a sell?
    • Can you buy or sell Medicamen Biotech Ltd. shares when the stock is at the lower circuit?
    • What happens the next trading session after a lower circuit?
    • What is the lower circuit limit set at for Indian stocks?
  • Footer Disclosure

Key Takeaways

  • Medicamen Biotech Ltd. hit the lower circuit on BSE at Rs 307.75 on 24 September 2026.
  • The session move was -4.99% against a previous close of Rs 323.9.
  • Market capitalisation stood at Rs 439.3 crore with a PE ratio of 40.57.
  • No official company announcement or verified catalyst was confirmed at the time of writing.
  • A price band is an exchange trading rule, not a view on the company or a recommendation.

Key Market Data

Metric Value
Stock Medicamen Biotech Ltd.
Current Price / LTP Rs 307.75
Day Move -4.99%
Previous Close Rs 323.9
Day Open Rs 320
Day High Rs 325
Day Low Rs 307.75
Lower Circuit Price Rs 307.75
Lower Circuit Limit Rs 307.75
Market Cap Rs 439.3 crore
Selected Exchange BSE
PE Ratio 40.57

All figures above are as of 24 September 2026, sourced from Univest market data for the BSE listing. Only fields present in the source for this session are shown.

Price Action and Trading Activity

Medicamen Biotech Ltd. opened at Rs 320 on BSE, compared with a previous close of Rs 323.9. During the session, the stock traded between Rs 307.75 and Rs 325 before touching the lower circuit price of Rs 307.75.

The absolute day change was Rs 16.15, while the percentage move was -4.99%. The event figures are kept to a single exchange so the numbers stay comparable.

The selected exchange matters because price bands, day range and previous-close values can differ across exchanges. This article uses BSE consistently for the event table and narrative. The stated lower circuit limit for the session was Rs 307.75, which is the level the price reached.

Why Medicamen Biotech Ltd. Hit Lower Circuit

Medicamen Biotech Ltd. hit the lower circuit after selling pressure pushed the stock to its exchange-defined price band. No official company announcement or verified external catalyst was confirmed at the time of writing, so the move should be read primarily through price action and market sentiment.

Because no verified catalyst was available, this article does not attribute the move to earnings, corporate action, sector news, or market rumours. If a confirmed announcement becomes available later, it should be added as a separate update.

Within the session the stock reached the lower circuit level of Rs 307.75.

What the Lower Circuit Means

A lower circuit is the minimum price level a stock is allowed to reach during a trading session under the applicable exchange price band. For Medicamen Biotech Ltd., the captured lower circuit price was Rs 307.75 on 24 September 2026.

The circuit mechanism is meant to slow extreme price movement and keep trading orderly. It is a market-structure fact, not a return forecast. In this article, the lower circuit explains what happened in the session and where the price band was reached.

Medicamen Biotech Ltd. Fundamentals and Valuation

Available market data gives a fuller picture than price action alone. For Medicamen Biotech Ltd., PE ratio was 40.57, PB ratio was 1.62, book value was Rs 199.52, EPS was 7.98, ROE was 3.23%, ROCE was 5.77%, dividend yield was 0.31% and debt-to-assets ratio was 0.16, on a market cap of Rs 439.3 crore. These are available financial indicators and should not be read as a buy, sell, or hold view.

A PB ratio above 1 means the market price was above the reported book value per share. That premium can reflect growth expectations, asset quality, or simply thin trading in a smaller counter.

For investors tracking lower circuit moves, these metrics help separate the price event from the broader financial profile. A sharp one-day move can attract attention, but valuation and return ratios still need to be reviewed separately.

Peer and Sector Context

Medicamen Biotech Ltd. belongs to the Pharmaceuticals & Drugs industry within the Healthcare sector. The peer table below uses available companies from the same sector or industry to give broader valuation context.

Peer Company Market Cap PE PB ROE
Hikal Ltd. Rs 2809.41 crore – 2.41 –
Dishman Carbogen Amcis Ltd. Rs 2663.74 crore 168.23 0.41 –
Sakar Healthcare Ltd. Rs 2644.18 crore 71.66 7.73 –
Panacea Biotec Ltd. Rs 2350.19 crore – 2.79 –
Indoco Remedies Ltd. Rs 2347.74 crore 412.58 2.33 –

A dash in the PE column means no PE ratio was carried for that company in the source data, which happens when reported earnings are negative or have not been refreshed. Those companies are left out of the average below rather than counted as zero.

Several of these peers are far larger by market capitalisation than Medicamen Biotech Ltd. Size differences change liquidity and cost of capital, so the table is sector context rather than a like-for-like ranking.

Medicamen Biotech Ltd.’s PE ratio was 40.57, compared with an available peer/sector PE average of 51.81, calculated from the 3 peer companies that had a PE on record. This comparison is a valuation reference point, not a recommendation.

Want to know more? Log in to Univest for more stock insights.

Technical and Ownership Snapshot

The technical snapshot adds context: RSI was 73.38, the 50-day moving average was 280.26 and the 200-day moving average was 269.23.

Worth flagging: the RSI reading sits on the opposite side of neutral to the day move and the last traded price and the 50-day average point in different directions. Indicator values in the dataset can lag the live session, so they should be checked against a live chart before being relied on.

Shareholding details were not available in the latest market dataset, so no conclusion is drawn about promoter, institutional, or public-shareholder activity.

What Readers Should Know

The main confirmed fact is that Medicamen Biotech Ltd. hit the lower circuit on BSE at Rs 307.75 on 24 September 2026, with a 4.99% day move.

The practical limitation after a lower-circuit session is execution. Sellers queue at the band with few buyers, so exiting at the quoted price may not be possible. The other limitation is that no official catalyst was confirmed at the time of writing.

Readers should treat lower circuit events as market updates, not standalone investment conclusions. The price band shows heavy near-term selling pressure, but follow-up analysis should consider business fundamentals, valuation, liquidity, risk, and confirmed company disclosures.

Frequently Asked Questions

Why did Medicamen Biotech Ltd. hit lower circuit on 24 September 2026?

The stock reached its lower price band after selling pressure during the session. No official company announcement or verified external catalyst was confirmed at the time of writing.

What was Medicamen Biotech Ltd. share price on 24 September 2026?

The last traded price used in this article was Rs 307.75 on BSE. That price matched the lower circuit price captured for the event.

What was the lower circuit price for Medicamen Biotech Ltd.?

The lower circuit price was Rs 307.75. The stated exchange lower circuit limit was Rs 307.75. The event numbers in this article are aligned to BSE.

What is Medicamen Biotech Ltd.’s market cap and PE ratio?

Medicamen Biotech Ltd.’s market cap was Rs 439.3 crore. PE ratio was 40.57.

Which exchange and data source were used?

The selected exchange was BSE. The article uses Univest market data available at the time of generation, captured on 24 September 2026.

Does hitting a lower circuit mean Medicamen Biotech Ltd. is a buy or a sell?

No. A circuit is an exchange price-band rule that caps how far a stock can move in a single session. It carries no view on valuation or business quality and is not a recommendation. Any decision should rest on fundamentals, valuation, liquidity and your own risk tolerance.

Can you buy or sell Medicamen Biotech Ltd. shares when the stock is at the lower circuit?

It is usually difficult. At the lower circuit, sell orders queue up with few buyers, so exiting at the quoted price may not be possible. Orders can stay unfilled until buying interest returns.

What happens the next trading session after a lower circuit?

There is no fixed outcome. The band resets each session, so the stock can open freely, hit the same band again, or reverse. The exchange can also revise the applicable band width. The useful signals to watch are whether the company files any disclosure explaining the move.

What is the lower circuit limit set at for Indian stocks?

Exchange price bands are commonly set at 2%, 5%, 10% or 20% depending on the security, and the applicable band can be revised by the exchange. For Medicamen Biotech Ltd. the stated limit was Rs 307.75. For this session, Medicamen Biotech Ltd. moved 4.99%.

Footer Disclosure

Uniresearch Global Pvt. Ltd.
Research Analyst
SEBI Registration Number- INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply